The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- “Cures” Bill Ready For House Vote: New Pay-Fors Include Authorized Generic Change, Lower Cap On Antibiotic Incentives Jul. 02, 2015
- Medicaid Demonstrations Hearing Takes Aim At ACA Expansion Waivers Jul. 01, 2015
- Purdue OxyContin Label Change To Reflect Impact On Abuse Withdrawn; FDA Likely To Cancel July 7-8 Meeting Jun. 30, 2015
See More Research Notes